Drug intelligence / Profile preview

DS-2741a

Development stage: Discontinued
Lead developer: Daiichi Sankyo
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

DS-2741a is a humanized monoclonal antibody that targets and inhibits the calcium release-activated calcium channel protein 1 (ORAI1), which forms the pore of the CRAC (calcium release-activated calcium) channel. ORAI1 is essential for store-operated calcium entry in lymphocytes and plays a critical role in T cell and mast cell activation. By inhibiting ORAI1, DS-2741a suppresses T-cell activation and mast cell degranulation, leading to reduced skin inflammation in animal models of atopic dermatitis. The drug was developed by Daiichi Sankyo primarily for immune-mediated diseases such as atopic dermatitis but development has been discontinued after phase 1 trials[1][2][3][4].

Targets

ORAI1 (Calcium release–activated calcium channel protein 1)

Beyond the preview

Go deeper on DS-2741a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DS-2741a.

Explore the full profile